TARRYTOWN, N.Y. - A COVID-19 antibody cocktail developed by U.S. drugmaker Regeneron offered strong protection against symptomatic infection when given to people living with someone else infected with ...
Nov 17 (Reuters) - Roche Holding AG (ROG.S), opens new tab has completed early tests of its ability to produce large quantities of Regeneron Pharmaceuticals Inc's (REGN.O), opens new tab COVID-19 ...
Many healthcare workers aren’t using COVID-19 antibody drugs from Eli Lilly and Regeneron, citing lack of data and staffing shortages, The Wall Street Journal reports. On average, Operation Warp Speed ...
Zacks Investment Research on MSN
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...
It’s far from business as usual at the Indianapolis headquarters of Eli Lilly, with only a sixth of the pharma company’s employees working on-site to develop potential Covid-19 treatments. WSJ’s Peter ...
Oct 7 (Reuters) - Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron ...
The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo(cemiplimab-rwlc) as an adjuvant therapy for adults with cutaneous ...
New results extend hopes for drugs that supply antibodies to fight COVID-19, suggesting they can help keep patients out of the hospital and possibly prevent illness in some uninfected people. Eli ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initiation of the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback